Telemus Capital’s Niagen Bioscience NAGE Stock Holding History

Telemus Capital’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,700	Closed	-$10K	–	577
2017 Q4	$10K	Buy	+1,700	New	+$9.18K	﹤0.01%	518

Other funds holding NAGE

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Telemus Capital's NAGE Position: Q1 2018 in Review

Telemus Capital sold out of Niagen Bioscience (NAGE) in Q1 2018, closing a stake of 1,700 shares — an estimated $10K sold.

Telemus Capital first reported a position in NAGE in Q4 2017 and held it in 1 quarter. The position peaked at $10K in Q4 2017. 58 funds tracked by Wall St. Rank hold NAGE as of Q1 2018.

Telemus Capital reported no remaining Niagen Bioscience position as of Q1 2018 after selling out during the quarter.
Telemus Capital sold 1,700 Niagen Bioscience shares in Q1 2018, an estimated $10K.
Telemus Capital first reported a position in Niagen Bioscience in Q4 2017 and held it in 1 quarter.
Telemus Capital's Niagen Bioscience position peaked at $10K in Q4 2017.
58 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2018.

Based on Telemus Capital's 13F filing for Q1 2018, filed 27 Apr 2018.